Literature DB >> 272230

N-trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies.

L M Parker, M Hirst, M Israel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 272230

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  6 in total

1.  Comparative effects of adriamycin and DNA-non-binding analogues on DNA, RNA, and protein synthesis in vitro.

Authors:  M Israel; J M Idriss; Y Koseki; V K Khetarpal
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 2.  Cancer chemotherapy: new developments and changing concepts.

Authors:  S K Carter
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

3.  Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.

Authors:  M Israel; A M Karkowsky; V K Khetarpal
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study.

Authors:  T W Sweatman; R F Parker; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.

Authors:  H B Niell; R F Hunter; H G Herrod; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32). Comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine.

Authors:  M Israel; A M Karkowsky; W J Pegg
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.